ATE486937T1 - Chimärische heteromultimerische adhesine - Google Patents

Chimärische heteromultimerische adhesine

Info

Publication number
ATE486937T1
ATE486937T1 AT97932526T AT97932526T ATE486937T1 AT E486937 T1 ATE486937 T1 AT E486937T1 AT 97932526 T AT97932526 T AT 97932526T AT 97932526 T AT97932526 T AT 97932526T AT E486937 T1 ATE486937 T1 AT E486937T1
Authority
AT
Austria
Prior art keywords
adhesins
chimeric
heteromultimeric
erbb2
heteromultimer
Prior art date
Application number
AT97932526T
Other languages
English (en)
Inventor
Vincent Fizpatrick
Mark Sliwkowski
Richard Vandlen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE486937T1 publication Critical patent/ATE486937T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Adhesives Or Adhesive Processes (AREA)
AT97932526T 1996-07-12 1997-07-08 Chimärische heteromultimerische adhesine ATE486937T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2164096P 1996-07-12 1996-07-12
US79832697A 1997-02-10 1997-02-10
PCT/US1997/011825 WO1998002540A1 (en) 1996-07-12 1997-07-08 Chimeric heteromultimer adhesins

Publications (1)

Publication Number Publication Date
ATE486937T1 true ATE486937T1 (de) 2010-11-15

Family

ID=26694954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97932526T ATE486937T1 (de) 1996-07-12 1997-07-08 Chimärische heteromultimerische adhesine

Country Status (13)

Country Link
US (3) US6696290B2 (de)
EP (2) EP0912734B1 (de)
JP (2) JP4274581B2 (de)
CN (1) CN1202247C (de)
AT (1) ATE486937T1 (de)
AU (1) AU722178B2 (de)
BR (1) BR9710357A (de)
CA (1) CA2258721C (de)
DE (1) DE69740038D1 (de)
DK (1) DK0912734T3 (de)
IL (1) IL127891A0 (de)
NZ (1) NZ333325A (de)
WO (1) WO1998002540A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2338299A (en) * 1998-01-26 1999-08-09 Genentech Inc. Antibodies to death receptor 4 (dr4) and uses thereof
EP1745799B1 (de) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Zusammensetzungen und Verfahren zur Behandlung von Tumoren
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ATE405651T1 (de) * 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20030022233A1 (en) * 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
DE60123998T2 (de) 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP4314113B2 (ja) * 2001-07-31 2009-08-12 ウェイン・ステイト・ユニバーシティ ヘパラン硫酸プロテオグリカンに対する標的化のための、ニューレグリンヘパリン結合ドメインとのハイブリッドタンパク質
EP1283053A1 (de) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitore der HER3 Aktivität
AU2003218600C1 (en) * 2002-03-26 2009-12-17 Zensun (Shanghai) Science & Technology Co., Ltd. ERBB3 based methods and compositions for treating neoplasms
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2004048525A2 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
CA2519227C (en) 2003-03-19 2013-12-03 Biogen Idec Ma Inc. Nogo receptor binding protein
ATE517914T1 (de) * 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
US8486893B2 (en) 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
AU2005299809B2 (en) 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
HRP20131066T1 (hr) 2005-07-08 2013-12-06 Biogen Idec Ma Inc. Sp35 antitijela i njihova upotreba
RU2423381C2 (ru) * 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
JP5312039B2 (ja) * 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
CN101611150A (zh) * 2006-02-08 2009-12-23 利佳赛普特有限责任公司 二价ErbB配体结合分子及其制备和使用方法
CA2642516A1 (en) * 2006-02-08 2007-08-16 Targeted Molecular Diagnostics, Llc Bivalent erbb ligand binding molecules and methods for their preparation and use
SG170021A1 (en) 2006-02-23 2011-04-29 Novocell Inc Compositions and methods useful for culturing differentiable cells
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
JP2009539412A (ja) * 2006-06-12 2009-11-19 レセプター バイオロジックス， インコーポレイテッド 汎細胞表面レセプター特異的な治療薬
EP2035452B1 (de) * 2006-06-22 2012-04-25 Novo Nordisk A/S Lösliche heterodimere rezeptoren und ihre verwendung
JP2009541275A (ja) * 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
WO2009048605A1 (en) * 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
AU2008312580A1 (en) * 2007-10-16 2009-04-23 Symphogen A/S Compositions comprising optimized Her1 and Her3 multimers and methods of use thereof
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
RU2531754C2 (ru) * 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
CA2729961C (en) * 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
WO2010019952A2 (en) * 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
US9198952B2 (en) 2008-09-22 2015-12-01 The Brigham And Women's Hospital, Inc. Compositions of and methods of using ligand dimers
MX2011005382A (es) 2008-11-25 2011-07-20 Genentech Inc Anticuerpos anti-her4 especificos de isoforma.
RU2012105766A (ru) * 2009-07-28 2013-09-10 Лигацепт, Лимитед Лиабилити Компани МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ ШИРОКИЙ СПЕКТР ЛИГАНДОВ ErbB И СПОСОБЫ ИХ ПРИГОТОВЛЕНИЯ И ИСПОЛЬЗОВАНИЯ
US9556249B2 (en) * 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012103114A2 (en) * 2011-01-24 2012-08-02 Jason Hill Therapeutic chimeric ligand binding proteins and methods for their use
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
WO2014051567A1 (en) * 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
EP3711484A1 (de) * 2013-07-05 2020-09-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Lösliches cd33 zur behandlung myelodysplastischer syndrome (mds)
EP3087394A2 (de) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarkerprofile zur vorhersage der ergebnisse einer krebstherapie mit erbb3-inhibitoren und/oder chemotherapien
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
KR20180117529A (ko) 2017-04-19 2018-10-29 주식회사 프로티나 단백질-단백질 상호작용 분석에 의한 약물 반응성 예측 방법
WO2019132517A1 (ko) * 2017-12-26 2019-07-04 주식회사 프로티나 세포 내 또는 세포 간 단백질-단백질 상호작용 분석 방법 및 장치
CN110669139B (zh) * 2019-09-18 2025-12-02 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
WO1990006953A2 (en) 1988-12-22 1990-06-28 Genentech, Inc. Method for preparing water soluble polypeptides
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0444961A1 (de) 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: Ein neues EGF-Rezeptor Homologes
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5254536A (en) * 1992-01-10 1993-10-19 The Du Pont Merck Pharmaceutical Company Therapeutic utility of plasminogen activator inhibitor-1 to control bleeding
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US6025145A (en) 1993-11-23 2000-02-15 Genentech, Inc. Kinase receptor activation assay
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides

Also Published As

Publication number Publication date
AU722178B2 (en) 2000-07-27
CA2258721A1 (en) 1998-01-22
EP0912734B1 (de) 2010-11-03
IL127891A0 (en) 1999-10-28
US6696290B2 (en) 2004-02-24
CN1202247C (zh) 2005-05-18
JP2008115187A (ja) 2008-05-22
AU3596297A (en) 1998-02-09
US20030199020A1 (en) 2003-10-23
WO1998002540A1 (en) 1998-01-22
US7659368B2 (en) 2010-02-09
NZ333325A (en) 2000-06-23
JP4274581B2 (ja) 2009-06-10
BR9710357A (pt) 1999-08-17
EP0912734A1 (de) 1999-05-06
US20070081994A1 (en) 2007-04-12
EP0938556B1 (de) 2005-03-09
JP2000515372A (ja) 2000-11-21
CA2258721C (en) 2014-09-09
DE69740038D1 (de) 2010-12-16
EP0938556A1 (de) 1999-09-01
US20040138417A1 (en) 2004-07-15
DK0912734T3 (da) 2011-02-07
CN1225129A (zh) 1999-08-04

Similar Documents

Publication Publication Date Title
ATE486937T1 (de) Chimärische heteromultimerische adhesine
ATE290595T1 (de) Gamma-heregulin
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
ATE262037T1 (de) Modifizierte liganden für den tie-2-rezeptor
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
MA32449B1 (fr) Agents de liaison de notch et antagonistes de notch ainsi que procedes d'utilisation correspondants
DE69129990D1 (de) Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
DE69637570D1 (de) Varianten des wachstumsfaktors der vaskulären endothelzellen, ihre verwendung sowie methoden für ihre herstellung
BG104268A (en) Bitumen or asphalt for producing road surfacing, road surfacing and method for the preparation of bitumen or asphalt
ATE361364T1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
IS5543A (is) Nýr G próteintengdur viðtaki
ATE527357T1 (de) Agonistischer antikörper gegen proteintyrosinkinase sal-s1
EP1071460A4 (de) Internalisierende erb2 antikörper
MA28702B1 (fr) Composes et procedes pour l'inhibition de l'interaction de proteines bcl avec des partenaires de liaison
NZ329807A (en) NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
AU5588094A (en) The pct-65 serotonin receptor
PT1283217E (pt) Anticorpos contra o receptor de il-8, e suas utilizações terapêuticas
EP1456239A4 (de) Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin-bindungsdomäne
EP0804576A4 (de) Hemopoietin-Rezeptor
AU7450096A (en) Cloning of vertebrate pheromone receptors and uses thereof
MX9603045A (es) Antagonistas de los receptores endoteliales.
NO975565L (no) Benstimulerende faktor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties